Introduction
With more than 36 million people cured of tuberculosis between 1995 and 2008 1 and 9 million new cases diagnosed worldwide each year, 2 the health of those affected over the long term warrants attention. Treated pulmonary tuberculosis (PTB) can lead to complications, including progressive loss of lung function, 3 persistent pulmonary symptoms 3 and chronic pulmonary aspergillosis (CPA). [4] [5] [6] Of the long-term sequelae of PTB, CPA is perhaps the most subtle, yet the most severe. [4] [5] [6] [7] [8] [9] [10] [11] In the 1960s the Research Committee of the British Thoracic and Tuberculosis Association estimated the prevalence of CPA in patients who had a residual cavity of at least 2.5 cm on the chest radiograph following treatment for PTB. 9, 12 It assessed more than 500 patients from 55 chest clinics twice -once about 12 months after the sputum became negative for acid fast bacilli, 12 and again three years later. 9 Remarkably, 25% of the patients had detectable Aspergillus precipitins in blood and both precipitins and radiological features of an aspergilloma were detectable in 14% at 12 months and in 22% at 3-4 years. PTB and CPA present with similar symptoms. This, combined with inadequate facilities for testing for immunoglobulin G (IgG) antibodies (precipitins) against A. fumigatus in many places, probably results in the underdiagnosis of CPA both at initial presentation 13 and following treatment for PTB. For example, in early case series of people with respiratory illness and negative acid fast bacillus (AFB) sputum smears in sub-Saharan Africa, A. fumigatus was among the pathogens identified.
14 CPA is an important differential diagnosis of what appears to be smear-negative tuberculosis.
CPA occurs in various forms: simple aspergilloma, chronic cavitary pulmonary aspergillosis and chronic fibrosing pulmonary aspergillosis, both with and without an aspergilloma. 4 Unlike invasive aspergillosis, CPA occurs in immunocompetent patients. Morbidity is considerable and is marked by both systemic and respiratory symptoms and haemoptysis. 7, 8 Weight loss, profound fatigue, severe shortness of breath and life-threatening haemoptysis are common. Progressive pulmonary fibrosis and loss of lung function, also common, could partly account for the unexplained loss of lung function in these patients. Even when treated, CPA has a case fatality rate of 20-33% in the short-term and of 50% over a span of 5 years. 5, 8 The country-specific PTB statistics and mortality rates published by the World Health Organization (WHO) 15 make it possible to estimate the burden of chronic sequelae after treatment for PTB. Our objective was to use these published clinical and population data as inputs to model estimates of the likely burden of CPA related to PTB worldwide.
Methods
We developed a deterministic scenario model using Excel (Microsoft, Bellevue, United States of America). Fig. 1 shows our approach to estimating the adult burden of CPA in the largest countries of every WHO region. We started with WHO estimates of the number of new cases of PTB and of deaths from PTB 15 and assumed that the mortality figures quoted by the WHO were for the point 12 months after the diagnosis of PTB.
Objective To estimate the global burden of chronic pulmonary aspergillosis (CPA) after pulmonary tuberculosis (PTB), specifically in cases with pulmonary cavitation. Methods PTB rates were obtained from the World Health Organization and a scoping review of the literature was conducted to identify studies on residual pulmonary cavitation after PTB and estimate the global incidence of CPA after PTB. Having established that from 21% (United States of America) to 35% (Taiwan, China) of PTB patients developed pulmonary cavities and that about 22% of these patients developed CPA, the authors applied annual attrition rates of 10%, 15% and 25% to estimate the period prevalence range for CPA over five years. Analysis was based on a deterministic model. Findings In 2007, 7.7 million cases of PTB occurred globally, and of them, an estimated 372 000 developed CPA: from 11 400 in Europe to 145 372 in South-East Asia. The global five-year period prevalence was 1 174 000, 852 000 and 1 372 000 cases at 15%, 25% and 10% annual attrition rates, respectively. The prevalence rate ranged from < 1 case per 100 000 population in large western European countries and the United States of America to 42.9 per 100 000 in both the Democratic Republic of the Congo and Nigeria. China and India had intermediate five-year period prevalence rates of 16.2 and 23.1 per 100 000, respectively. Conclusion The global burden of CPA as a sequel to PTB is substantial and warrants further investigation. CPA could account for some cases of smear-negative PTB. Since CPA responds to long-term antifungal therapy, improved case detection should be urgently undertaken.
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We searched the literature with the following questions in mind: (i) What is the frequency of pulmonary cavitation after completion of the treatment for PTB? (ii) How common is CPA following PTB? (iii) Are there any radiological risk factors (such as cavitation) for CPA? (iv) What is the range of the 12-month survival for PTB (to estimate the numbers at risk of developing CPA development)? and (v) What is the range of the 12-month survival for CPA (to estimate attrition and convert incidence to period prevalence)? We initially adopted a systematic search strategy but quickly realized that the literature was limited and that scoping reviews for all five questions were more appropriate. 16 To identify the primary literature on cavitation after PTB, we searched several electronic bibliographic databases using the search terms "tuberculosis" and all of (separately) "follow up", "radiology", "cavitation", "cavity", "CT", "radiograph", "radiographic", "outcome", "fungal ball", "aspergilloma", "aspergillosis" and "haemoptysis" (using both British and American English spellings). All literature on aspergilloma was retrieved back to 1936. Our primary source was Medline, but we also searched the Aspergillus web site (including the historical paper archive [pre-1964] ). We did not search meeting abstracts, doctoral theses or other grey literature sources, but we hand searched our extensive files of pre-1990 papers on all forms of aspergillosis. Every paper retrieved with information on cavitation following PTB was scrutinized and additional referenced papers were also retrieved. The term "aspergilloma" entered the medical literature in the 1940s, but the phrase "chronic pulmonary aspergillosis" was not formally used until 2003. Thus, searches with the terms "aspergillosis" and "aspergilloma" yielded very different numbers of papers. We initially identified over 400 papers and scanned their abstracts. We read over 100 papers to determine the availability of data on the treatment of pulmonary cavitation. Five sources contained relevant quantitative information on cavitation; the rest contained only qualitative data. To minimize selection bias, we established as inclusion criteria a cohort study or case series design and a minimum of 20 study subjects. We also contacted the original authors of the primary combination studies of PTB conducted by the Medical Research Council of the United Kingdom of Great Britain and Northern Ireland to establish if the original end-of-treatment chest radiographs or readings were available for review. Unfortunately, they were not.
We identified five papers that provided data on the proportion of cases with pulmonary cavities following antituberculous therapy. The studies yielded different figures: they ranged from 21% in the United States 17 to 35% in Taiwan, China 18 and > 50% in South Africa in some studies, 19 (Table 1) . We decided on an intermediate figure of 22% and applied it to countries across the globe except for the 22 members of the European Community. For Europe we took into account our own (unpublished) observations from the United Kingdom, which showed a post-treatment cavitation rate of less than 10%, and selected an intermediate figure of 12% that will require prospective validation. We also performed sensitivity analyses using figures of 10% and 30% for countries outside the European Community. We examined the papers found through our searches for data on the frequency of an association between PTB and either aspergilloma or chronic pulmonary aspergillosis, as well as on the radiological characteristics of these entities. We excluded case reports, qualitative studies and papers describing an association with invasive aspergillosis. Papers reporting the frequency of aspergilloma or fungal balls without serological confirmation were included but those describing cavitation without a fungal ball were included only if CPA was confirmed serologically or through direct histological exam or culture of the lesions. Finally, only two papers from the same Medical Research Council study in the United Kingdom linked radiological findings with the subsequent development of aspergilloma (and included serologic testing for Aspergillus) and, therefore, chronic pulmonary aspergillosis (Fig. 2) . 9, 12 The figures shown in Fig. 2 were checked and confirmed by all authors. We found no papers describing the rate of CPA after PTB without reference to pulmonary cavitation or in patients without cavitation.
On a country by country basis, we multiplied the number of survivors 12 months following initiation of therapy for PTB by the designated percentage of patients with pulmonary cavities. We then estimated the number of patients with cavities who were likely to develop CPA (22% according to the studies from the United Kingdom, 9, 12 Fig. 2 ). We found little published data on CPA among patients without visible cavities on a chest radiograph following PTB, so we chose 2% as the best estimate, with upper and lower bounds of 1% and 4% for sensitivity analyses. This allowed us to estimate the number of cases with CPA 1 year following completion of treatment of PTB.
The purpose of the fourth review was to establish the range of survival rates 12 months after diagnosis of PTB. A full systematic review could have been conducted to address this question, but since the rates of survival were used to identify patients at risk for CPA for modelling purposes only, we chose to perform a scoping review to establish the survival range. We assumed that all cases of PTB had been correctly diagnosed in these studies. Five studies were identified and 12-month mortality following PTB ranged from 5% to 26%.
We also conducted a scoping review to estimate12-month survival after the development of CPA and found only three published studies that allowed us to make such an estimate (85%) and convert annual incident cases into five-year period prevalence. Patients undergoing 
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Chronic aspergillosis after pulmonary tuberculosis David W Denning resection surgery for aspergilloma are so few compared with the number who die from CPA that we did not estimate their proportion. Long-term survival from PTB varies widely and is affected by co-infection with the human immunodeficiency virus (HIV), age, treatment adherence and the presence of multidrug-resistant or extensively drug-resistant PTB (MDR-PTB and XDR-PTB, respectively). Annual mortality following PTB has been shown to vary from < 2% in Denmark 22 and 9% in Guinea-Bissau 23 to 15% in Uzbekistan. 24 (Table 2) . Annual mortality from MDR-PTB may be no higher than mortality from PTB responsive to medication (41% over 5 years), 26 but it is higher in HIV-positive individuals (26%) before they are treated with antiretroviral therapy. 25, 27 Thus, to estimate the five-year period prevalence of CPA as a complication of PTB, we applied 10%, 15% and 25% annual attrition rates to deduct deaths annually over the 5-year period.
All papers retrieved that contained quantitative data were reviewed by all authors to ensure that the samples surveyed in each paper were not highly selected and hence biased. The proportions of patients with pulmonary cavities and the annual post-treatment mortality rates were extracted independently by two authors (DWD and DCC) and discrepancies were resolved by discussion. The list of excluded papers is available from the authors on request.
Results
According to WHO, in 2007 an estimated 7.7 million cases of PTB occurred worldwide, and 5.96 million (77.1%) of them survived to at least 12 months after diagnosis. Nearly 50% of these cases occurred in China and India, whose combined population in 2005 was 2.4 billion ( Table 3) . 28 We estimate that annually at least 372 385 patients in EOT, end-of-treatment; HIV, human immunodeficiency virus; MDR, multi-drug resistant; PTB, pulmonary tuberculosis; RCT, randomized controlled trial; TB, tuberculosis. (Table 4) . However, minimum estimates were 98 551 for the African Region, 83 815 for the Western Pacific Region and 145 372 for the South-East Asia Region. Individual country estimates for the 24 most populous countries are provided in Table 3 .
Our best estimate of the global fiveyear period prevalence of CPA following PTB was 1 173 881 patients, with a range from 852 048 at 25% annual attrition to 1 372 457 at 10% annual attrition (Table 4) . Sensitivity analyses using rates of cavitation after PTB of 10% and 30% and rates of CPA in people without cavities of 1% and 4% altered the estimates from a low global five-year period prevalence of 546 844 to a high of 1 786 421 when a 15% attrition rate was applied.
The five-year period prevalence of CPA indicated a predicted prevalence rate of 18 per 100 000 population (Table 3 ). The prevalence rate of CPA varies widely, however. Among the 23 largest countries in the world it ranges from as low as 0.4 per 100 000 in Germany to 42.9 per 100 000 in both Nigeria and the Democratic Republic of the Congo. China and India have intermediate predicted prevalence rates of 16.2 and 23.1 per 100 000, respectively. In the largest developed countries, the predicted prevalence rate is invariably below 1 per 100 000.
Discussion
According to our model, which resembles many models used by WHO to estimate the burden of other diseases, around 1.2 million people in the world have CPA as a sequel to PTB. Most CPA cases occur in WHO's South-East Asia, Western Pacific and African regions, where PTB has the highest prevalence.
In many series PTB is an underlying condition among CPA cases, but this varies widely. Only 17% of referred CPA patients in Manchester, England, 29 had underlying PTB, compared with 93% in Seoul, Republic of Korea. 6 This variation reflects differences in clinician awareness, in diagnostic approaches in patients with persistent pulmonary shadowing, and in the relative frequency of underlying pulmonary diseases in each locality. The progressive loss of pulmonary function and/or the presence of symptoms after PTB could be caused by CPA, but this possibility has never been studied. In cases in which CPA is diagnosed, symptoms such as fatigue, cough, shortness of breath, weight loss and haemoptysis are best managed with antifungal therapy. Identifying CPA early in patients with residual pulmonary shadows from PTB is only possible by means of microbiological testing (principally for Aspergillus IgG antibodies). If tests are not conducted, patients are often diagnosed as having Of 491 treated, 239 (49%) were cured or completed treatment; 68 (14%) died. Of 410 patients who had not transferred out or died during treatment for MDR-PTB, 281 (69%) had 2-year data available: 185 (66%) were cured or completed treatment; 32 (11%) were retreated for PTB and 64 (23%) died. Analysis of five-year outcomes of 154/233 (66%) patients who were treated in cohorts 1992-1998 and were known to be alive at the end of treatment revealed that 77 (50%) were alive, 14 (9%) had been re-treated for drug-susceptible PTB and 63 (41%) had died EPTB, extrapulmonary tuberculosis; HIV, human immunodeficiency virus; MDR, multi-drug resistant; PYO, person-years of observation; TB, tuberculosis.
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Chronic aspergillosis after pulmonary tuberculosis David W Denning "smear-negative pulmonary tuberculosis", "progressive upper lobe fibrosis" or "recurrent pulmonary tuberculosis", all of which result in inappropriate therapy or none at all. In areas with a high prevalence of tuberculosis, criteria for the diagnosis of CPA and PTB are so similar that distinguishing between the two entities is not possible, without serological testing for Aspergillus precipitins, even if sputum culture is positive for A. fumigatus.
14

Accuracy of pulmonary tuberculosis case estimates
We based our estimates of CPA prevalence following PTB on WHO tuberculosis rates. 15 The data are robust in some countries but not others. Underreporting is common, especially in countries such as China. Therefore, we have probably underestimated the burden of CPA. In addition, both incident cases and cure rates are changing relatively rapidly, thanks to the Stop TB Partnership. Case fatality rates dropped from 8% to 4% between 1995 and 2008. 1 A recent estimate of mortality in patients with HIV and TB co-infection yielded a rate of 5% for countries in Africa with a low prevalence of HIV infection, but closer to 20% in those with a high prevalence, 25 consistent with our estimates. Increased survival is likely to lead to greater numbers of people at risk of sequelae, including CPA. Estimating post-treatment survival was challenging, mostly because accurately estimating prognostic denominators was difficult, as others have found.
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CPA case ascertainment
To estimate CPA burden we have used radiographic findings primarily. Our own data suggests that about 25% of patients with CPA have an aspergilloma. 30 The original United Kingdom survey on PTB was conducted with chest radiographs, yet computerized tomography (CT) scanning of the thorax is much more sensitive, especially in the apex of the lungs, which is the site of most PTB and CPA. The cavitation rates of 30% 18 and 35% 21 after PTB are based on CT, whereas estimates based on chest radiographs are generally 21-23%. 17, 20 An even higher rate of residual cavitation (> 50%) was demonstrated in a population with MDR-PTB. 19 We arbitrarily applied to all of Europe the cavitation rate in the United Kingdom instead of conducting a prospective assessment, a clear study limitation. Plain chest X-rays have reasonable sensitivity (70%) for the detection of pulmonary cavities when anti-tuberculous treatment is initiated and while it is being administered, but it drops by the end of treatment (49%) 17 and few centres undertake CT scans at that time. Although we have accounted for this variation in our upper and lower estimates, additional work is necessary to validate these frequencies in different populations, especially in North America and Europe. We recognize that a robust estimate of CPA based on rates of cavitation after PTB needs to be fully validated at the local level, especially in countries where data are old or do not exist, such as the United Kingdom. In addition to pulmonary cavitations on chest X-ray, with or without an aspergilloma, either the presence of hyphae in a pulmonary cavity (preferably with a positive culture) or the presence of Aspergillus IgG antibodies must be definitively demonstrated for the diagnosis of CPA to be made. Serologic tests for A. fumigatus IgG antibodies have a sensitivity of about 90% for CPA. 31, 32 Rare cases of CPA caused by A niger, A. nidulans and A. flavus instead of the more common pathogen, A. fumigatus, have been documented 8, [33] [34] [35] and may be a source of false negative serology results. Thus, case detection is likely to be incomplete. Detectable Aspergillus desoxyribonucleic acid (DNA) in respiratory samples 36 could suggest CPA, prior to A. fumigatus IgG antibodies being requested.
Accounting for CPA-related mortality
CPA can be cured in 1% to 17% of patients who undergo surgery, usually within a year of diagnosis. 9, 11 Mortality from surgery is extremely low for simple aspergilloma [37] [38] [39] [40] but much higher for complex disease. 4, 11 Even with antifungal treatment, CPA develops gradually and leads to progressive loss of lung function. The case fatality rate after admission to hospital ranges from 10% to 30%. 6, 8, 10 We have therefore introduced an annual attrition rate of 15% by default, with a range from 10% to 25%, when converting annual incident cases to five-year period prevalence. In our experience, survival is determined primarily by the combined effect of the severity of the underlying pulmonary disease and the extent and pace of lung destruction.
Other risk factors
Many risk factors for CPA probably exist and they include some genetic defects. Deficiency of surfactant A2 and toll-like receptor 4 has been shown to alter innate immune function. 41, 42 In CPA patients, cytokine production profiles typically show a Th2 cytokine profile 41 and gamma interferon production may be absent or poor. 43 Other risk factors such as these, whose frequency probably varies in different ethnic groups, could affect both the incidence and progression of CPA.
Future directions
CPA is a sequel of PTB more commonly than is generally appreciated. It can account for progressive lung destruction and the persistence of symptoms after successful anti-tuberculous treatment and can mimic smear-negative PTB. Antifungal therapy is very beneficial in CPA patients, as it reduces both morbidity and mortality. [6] [7] [8] 30, [43] [44] [45] [46] Little data exist on the development of CPA after PTB. Prospective clinical and epidemiological studies using the best diagnostic tools available are needed to ascertain its frequency in different places and among different ethnic groups. Recognition of CPA and treatment with generic itraconazole have the potential to reduce morbidity and mortality from CPA worldwide at a modest cost. ■ 
Резюме
Глобальное бремя хронического пульмонального аспергиллеза, как осложнения туберкулеза легких Цель Оценить глобальное бремя хронического пульмонального аспергиллеза (ХПА), развившегося после излечения туберкулеза легких (ТБЛ), в частности, у больных с легочной кавитацией. Методы Показатели ТБЛ были получены от Всемирной организации здравоохранения. Был также выполнен оценочный обзор литературы с тем, чтобы выявить исследования, посвященные остаточной легочной кавитации после излечения ТБЛ, и провести глобальную оценку заболеваемости ХПА после излеченного ТБЛ. Установив, что от 21 (США) до 35% (Тайвань, Китай) пациентов с ТБЛ имели полости в легких, и что примерно у 22% этих больных развился ХПА, авторы применили годовые коэффициенты оттока, равные 10, 15 и 25%, чтобы оценить диапазон распространенности ХПА за пятилетний период. Анализ основывался на детерминистской модели. Результаты В 2007 году в мире произошло 7,7 млн случаев заболевания ТБЛ; из них, по оценкам, у 372 тыс. пациентов развился ХПА; разброс региональных показателей составлял от 11 400 случаев в Европе до 145 372 в Юго-Восточной Азии. Глобальная распространенность заболевания за пятилетний период составила 1 174, 852 и 1 372 тыс. случаев при годовом коэффициенте оттока в 15, 25 и 10%, соответственно. Коэффициент распространенности варьировался менее чем от одного случая на 100 тыс. чел. населения в крупных странах Западной Европы и в США до 42,9 случая на 100 тыс. чел. населения в Нигерии и Демократической Республике Конго. В Китае и Индии промежуточный показатель распространенности за пятилетний период составлял 16,2 и 23,1 случаев на 100 тыс. чел. населения, соответственно. Вывод Глобальное бремя ХПА, как осложнения ТБЛ, значительно и нуждается в углубленном исследовании. В некоторых случаях ХПА мог быть причиной заболевания ТБЛ с отрицательным мазком. Поскольку ХПА поддается лечению в случае длительного применения антигрибковой терапии, срочно необходимо повысить выявляемость случаев этого заболевания.
Resumen
Carga global de la aspergilosis pulmonar crónica como una secuela de la tuberculosis pulmonar Objetivo Calcular la carga global de la aspergilosis pulmonar crónica (APC) después de la tuberculosis pulmonar (TBP), específicamente, en casos con cavitación pulmonar. Métodos Se obtuvieron las tasas de TBP de la Organización Mundial de la Salud y se realizó una revisión de evaluación de la bibliografía con el fin de identificar los estudios sobre cavitación pulmonar residual después de la TBP y calcular la incidencia global de la APC después de la TBP. Habiendo establecido que del 21% (Estados Unidos de América) al 35% (Taiwán, China) de los pacientes con TBP desarrollaron cavidades pulmonares y que alrededor del 22% de dichos pacientes desarrollaron APC, los autores aplicaron tasas de abandono anuales del 10%, 15% y 25% para calcular el rango de prevalencia para la APC en un periodo de cinco años. Los análisis se basaron en un modelo determinista. Hallazgos En 2007, se produjeron 7,7 millones de casos de TBP en todo el mundo, de los cuales se calcula que unos 372 000 desarrollaron APC: desde 11 400 en Europa hasta 145 372 en Asia Sudoriental. La prevalencia global en un periodo de cinco años fue de 1 174 000, 852 000 y 1 372 000 casos con tasas de abandono anuales del 15%, 25% y 10%, respectivamente. La tasa de prevalencia osciló de < 1 caso por cada 100 000 habitantes en los grandes países de Europa Occidental y los Estados Unidos de América a 42,9 por cada 100 000 habitantes en tanto Nigeria como la República Democrática del Congo. China e India presentaron tasas intermedias de prevalencia en un periodo de cinco años de 16,2 y 23,1 por cada 100 000 habitantes, respectivamente. Conclusión La carga global de la APC como consecuencia de la TBP es sustancial, algo que justifica que se continúe investigando. La APC podría ser la responsable de algunos casos de TBP con frotis negativo. Dado que la APC responde al tratamiento antifúngico a largo plazo, es necesario mejorar con urgencia la detección de los casos.
